Toward pharmacogenetic SLCO1B1‐guided dosing of methotrexate in arthritis using a murine Slco1b2 knockout model
Abstract Low‐dose methotrexate (MTX) is a first‐line therapy for the treatment of arthritis. However, there is considerable interindividual variability in MTX exposure following standard dosing. Polymorphisms in SLCO1B1 significantly effect MTX clearance, altering therapeutic response. One decreased...
Enregistré dans:
Auteurs principaux: | Zachary L. Taylor, Lauren E. Thompson, Heather Bear, Tomoyuki Mizuno, Alexander A. Vinks, Laura B. Ramsey |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Wiley
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/a6b2dde967344193adb79c03c44199eb |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Abiraterone induces SLCO1B3 expression in prostate cancer via microRNA-579-3p
par: Roberto H. Barbier, et autres
Publié: (2021) -
A Cost–Consequence Analysis of Preemptive <i>SLCO1B1</i> Testing for Statin Myopathy Risk Compared to Usual Care
par: Charles A. Brunette, et autres
Publié: (2021) -
Highly expressed SLCO1B3 inhibits the occurrence and development of breast cancer and can be used as a clinical indicator of prognosis
par: Tiantian Tang, et autres
Publié: (2021) -
SLCO3A1, A novel crohn's disease-associated gene, regulates nf-κB activity and associates with intestinal perforation.
par: Shu-Chen Wei, et autres
Publié: (2014) -
An EAV-HP insertion in the promoter region of SLCO1B3 has pleiotropic effects on chicken liver metabolism based on the transcriptome and proteome analysis
par: Jianfei Chen, et autres
Publié: (2021)